HASKELL KIRKPATRICK, MD
Medical Oncology Physician · DALLAS, TX
Individual Active NPI 1356384200
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 807 | 225,986 | $16,755,483 | $4,327,430 | $3,453,846 |
| 2023 | 870 | 228,839 | $16,190,615 | $4,440,520 | $3,537,320 |
| 2022 | 835 | 203,120 | $14,971,533 | $4,379,822 | $3,490,275 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23,165 | $3 | $2 |
| J1453 | Injection, fosaprepitant, 1 mg | 22,500 | $0 | $0 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 16,980 | $0 | $0 |
| J1756 | Injection, iron sucrose, 1 mg | 14,200 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 12,200 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12,060 | $38 | $30 |
| J9271 | Injection, pembrolizumab, 1 mg | 10,500 | $56 | $45 |
| J9267 | Injection, paclitaxel, 1 mg | 4,638 | $0 | $0 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 4,000 | $46 | $37 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,597 | $0 | $0 |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,440 | $21 | $16 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1,860 | $1 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | L4021 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Texas
- NPI 1962595090
- NPI 1407898505
- NPI 1821257072
- NPI 1225328743
- NPI 1528591047
- NPI 1326368895
- NPI 1154530830
- NPI 1235171281
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.